Skip to content

Programs & Resources

Breast and Gynecologic Cancer Research Group

Programs and Projects

Breast Cancer Prevention Clinical Trials

Ongoing Phase I/II Prevention Trials Funded and Monitored by the Breast and Gynecologic Cancer Research Group (BGCRG)

Principal Investigator	Funding Mechanism	Title of Award	Chemopreventive Agent
Carol Fabian, MD**	R01	Breast Cancer Prevention by Letrozole in High Risk Women NCT00579826	Letrozole
Melanie Palomares, MD** City of Hope, Beckman Research Institute	R01	Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction NCT01196936	Tamoxifen
Jose Russo, MD Fox Chase Cancer Center	R21	Genomic Markers of Breast Cancer Prevention Induced by hCG in Women at High Risk	r-hCG
Howard Baily, MD University of Wisconsin	PhaseI/II Consortia Contract	A Randomized, Double-Blind, Single Dose and Multi-Dose Study of the Novel Retinoid, 9cUAB30 to Determine Pharmacokinetics and Safety	9-cis-UAB30
Sherry Chow, PhD University of Arizona	PhaseI/II Consortia Contract	Phase Ib Study of Resveratrol in Postmenopausal Women with High Body Mass Index	Resveratrol
Seema Khan, MD** Northwestern University	PhaseI/II Consortia Contract	Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women with Ductal Carcinoma In-situ of the Breast NCT00952731	Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen
Howard Baily, MD University of Wisconsin	PhaseI/II Consortia Contract	A Pilot Study of the Novel Retinoid, 9cUAB30 to Determine Preliminary Pharmacokinetics NCT00896974	9-cis-UAB30
Carol Fabian, MD** University of Kansas Medical Center	PhaseI/II Consortia Contract	A Phase II Study of Acolbifene in Premenopausal Women at High Risk for Breast Cancer NCT00853996	Acolbifene
Banu Arun, MD** MD Anderson Cancer Center	PhaseI/II Consortia Contract	A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer NCT00637481	Atorvastatin
Dawn Hershman, MD Columbia University	PhaseI/II Consortia Contract	Phase 1b Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with a History of Hormone Receptor-Negative Breast Cancer NCT00516243	Polyphenon E
Ray Bergan, MD Northwestern University	PhaseI/II Consortia Contract	A Phase IIB Trial of G - 2535 (Unconjugated Isoflavones -100) in Women at High Risk Breast Cancer NCT00290758	G - 2535 (Unconjugated Isoflavones -100) Placebo
Powel Brown, MD, PhD** MD Anderson Cancer Center	Monitoring	Lapatinib in Treating Women With Ductal Carcinoma In Situ of the Breast NCT00555152	Lapatinib
Jennifer Eng-Wong, MD Georgetown University Medical Center	Monitoring	Trial of Exemestane in Post-menopausal Women with DCIS or at High Risk for Invasive Breast Cancer NCT00073073	Exemestane
David Euhus, MD UT Southwestern Medical Center Dallas, Texas	Master Agreement	An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers That are Modulated by Tamoxifen vs. Placebo in Women with an Increased Risk for Breast Cancer	Tamoxifen

** indicates studies that are open to accrual